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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A405molecules to circulation in order to maintain the high-viscosity needed
for efﬁcient lubrication by synovial ﬂuid. One example of this challenge
is that most contrast-enhanced clinical imaging protocols deﬁne carti-
lage defects by exclusion of systemically delivered small molecule
contrast agents. This architecture presents a challenge to effective drug
delivery for treating OA. We hypothesized that cationic TAT-PTDs
(Peptide Transduction Domains) would enable in vivo drug delivery
into synovial joints because of electrostatic attraction between the
cationic TAT PTD and anionic cartilage glycosaminoglycans.
Methods: To address our hypothesis, we utilized a non-invasive in
vivo model of post-traumatic OA. In this model, joints are subjected
to a single mechanical overload which results in upregulation of IL-6
mRNA. 24 hours prior to injury, we treated the animals with siRNA
complexed to a TAT-PTD fusion protein for delivery of siRNA. The
fusion protein, TAT PTD-DRBD (Protein Transduction Domain cou-
pled to a Double-stranded RNA Binding Domain), was complexed to
siRNA at a 1:8 molar ratio of siRNA to protein. Controls included
both untreated and off-target-treated joints. Therapeutic com-
pounds and controls were delivered via 12 mL injection to the
selected knee joint using a medial approach. Joints were injured by a
single mechanical overload applied at 500 mm/s which results in a
mid-substance tear of the ACL. Joints were harvested for qPCR 1
week after injury.
Results: Injury resulted in upregulation of IL-6 mRNA in the injured
knee joint relative to the uninjured contralateral knee. There was
signiﬁcantly less upregulation of IL-6 mRNA in injured joints treated
with the PTD-DRBD complexed to an anti-IL-6 siRNA (p ¼ 0.027,
Figure 1) while treatment treated with off-target siRNA complexes had
no effect.
Conclusions: These data demonstrate the feasibility of in vivo bioactive
drug delivery to synovial joints using the TAT Peptide Transduction
Domain, in this example for delivery of siRNA to attenuate injury-
induced expression of IL-6. Future studies may utilize TAT fusion pro-
teins as well as the PTD-DRBD to advance both basic and translational
studies of osteoarthritis.
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INTRA-ARTICULAR AUGMENTATION OF LUBRICATION WITH SILK
MICROSPHERES
X. Wang, J. Guo, A. Tweed-Kent, A. Dovletoglou, D. Kaplan, A. Bellinger.
Cocoon Biotech, Boston, MA, USA
Purpose: Osteoarthritis of the knee represents a large unmet clinical
need. Deﬁcits in synovial lubrication have been reported in osteo-
arthritis, and several strategies to augment lubrication have shown
preclinical beneﬁt. We hypothesized that augmentation of the boun-
dary lubrication of synovial ﬂuid by intra-articular administration of
long-residence non-inﬂammatory lubricating silk microspheres could
reduce mechanical injury and pain in an osteoarthritis animal model.Methods: Silk microspheres with phospholipid coatings were prepared
by a modiﬁed version of previously published methods. Osteoarthritis
was induced in rats using the surgical instability model consisting of
MCL tear and meniscectomy. One week following injury, affected knees
were intra-articularly administered saline vehicle or silk microspheres
(2.5mg). Serial body weights, knee effusion, gait analysis on Day 14, and
Von Frey secondary allodynia testing on Days -1, 6, and 13 were
measured. Severity of osteoarthritis was assessed by histopathologic
analysis by a trained pathologist on Day 28 after injury.
Results: Silk microspheres with varying size distributions were syn-
thesized and achieved coefﬁcients of friction approaching 0.05 to 0.02.
Intra-articular injection of silk microspheres was well tolerated in rats
with no adverse reactions. Von Frey testing of secondary allodynia 6
days after injection indicated a trend towards a modest but sustained
reduction of osteoarthritic pain.
Conclusions: Intra-articular silk microspheres offer a novel, biologically
inert, non-inﬂammatory, and well tolerated potential therapy for
osteoarthritis. These results motivate further formulation optimization
of silkmicrosphere composition to tune synovial residence, degradation
proﬁle, lubrication properties, and potentially to provide prolonged
delivery of active therapeutics. Augmentation of joint lubrication with
silk microspheres merits further preclinical exploration as a novel
therapy to address the unmet need in osteoarthritis.
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BMI, AGE, RADIOGRAPHIC SEVERITY AND ULTRASOUND GUIDANCE
IMPACT THE RESPONSE TO HYALURONIC ACID INJECTIONS IN KNEE
OSTEOARTHRITIS
E. Wilder, R. Flanagan, E. Strauss, J. Samuels. NYU Langone Hosp. for Joint
Diseases, New York, NY, USA
Purpose:While hyaluronic acid (HA) viscosupplementation has shown
promise in the management of patients with knee osteoarthritis (KOA),
mixed outcome data has led both individual physicians and subspeci-
alty societies to question or eliminate its role in treatment algorithms.
We examined clinical predictors of response to HA injections in a pro-
spective study.
Methods: We screened consecutive patients at HA injections during
routine clinical visits to rheumatology, orthopedics or physiatry at NYU
Langone Medical Center, enrolling those 25 years old with KOA and
pain for 1 month and a visual analog scale pain score 30mm. Base-
line assessments included OA severity by the Kellgren-Lawrence (KL)
scale on knee radiographs within the year prior, a history of comor-
bidities and prior KOA treatment, and patient-reported questionnaires
including the Knee Injury and Osteoarthritis Outcome Score (KOOS),
and the Western Ontario McMasters Universities Osteoarthritis Index
(WOMAC) with a Likert scale calculated from the KOOS. We docu-
mented other variables such as the speciﬁc HA formulation, the ana-
tomic approach, and use of ultrasound guidance. Patients are
completing the questionnaires at 2, 6, 9 and 12 month intervals, but
only continue past 2 months as long as there was still some beneﬁt at
the preceding visit.
Results: Thus far we have screened 194 patients with (ongoing)
enrollment now at 107 (61% female, mean age 58 years ±11, range 27-
84). To date, the cohort’s mean BMI is 30.9 kg/m2±6.6, range 20.9-61.7,
well distributed by BMI subgroup (&lt25, 25-30¼overweight, 30-
35¼obese, and &gt35¼morbidly obese). At baseline, the mean KOOS
pain score (0¼worst, 100¼best) is 47.1 ±17.4, range 0-83.3, and the
WOMAC index (0¼best, 96¼worst) is 45.1±17.8, range 12-96, without a
signiﬁcant difference between the 4 BMI strata. X-rays have been scored
on 85 patients thus far (others are obtaining recent images from other
institutions), but neither the KOOS pain nor WOMAC index at baseline
trends with x-ray severity. Of 102 patients (5 withdrew), 38 have
completed their 2 month followup visits. Patients with a BMI&lt30
(n¼23) responded better than &gt30 (n¼15), both by KOOS pain (þ17.1
vsþ9.2, p¼0.09) andWOMAC index (-15.7 vs -9.2, p¼0.14), with similar
trends across other KOOS and WOMAC scores. The KOOS pain
improvements were better for radiographic grades KL2 and KL3 than
those seen for KL4 (þ 12.8 and þ15.1 vs þ5.9, p¼0.13 for KL 3vs4), as
were the WOMAC index scores (-19.3, -13.7 vs -6.5) The youngest
quartile (ages 37-54) responded better than the middle 2 and the oldest
quartile (ages 70-84) by KOOS pain (þ18.2, þ17.6, þ12.3, þ7.1, p¼0.04
